U.S. pharmaceutical giant Eli Lilly is exploring whether obesity drugs could be used to curb joblessness after signing a ...

Over the last couple of years, pharmaceutical giant Eli Lilly (NYSE: LLY) has made a splash in the red-hot weight loss space.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Since 2021, the Obesity Action Coalition (OAC) has led a national public awareness campaign against weight bias with a goal ...

Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies say this will limit patient access.

In a year and a half, Eli Lilly (NYSE: LLY) has roughly doubled in value. It is now the most valuable pharmaceutical company in the world.

按照协议，礼来公司将启动一项“真实世界”研究，旨在了解替西帕肽（tirzepatide，其Zepbound和Mounjaro药物背后的GLP-1受体激动剂药物）如何影响减肥、糖尿病预防和肥胖相关并发症的预防，以更好地为英国国家卫生服务局（NHS）应对 ...

Eli Lilly (NYSE:LLY) has partnered with the British ... tirzepatide, branded as Zepbound. Writing for the U.K.’s The Telegraph newspaper, Secretary of State for Health & Social Care Wes ...

Eli Lilly (LLY) has partnered with the government of the United Kingdom to see if its blockbuster weight loss drug could help ...

There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.

In a bid to combat obesity and unemployment, the UK govt is collaborating with Eli Lilly, which will invest £279 mn in a ...

In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities ...